Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi-Sankyo Slashing 1,000+ US Jobs Ahead Of Benicar Expiry

This article was originally published in PharmAsia News

Executive Summary

Japanese major Daiichi-Sankyo is preparing to cut up to 1,200 mainly sales positions in the US ahead of the loss of exclusivity for blockbuster antihypertensive Benicar, and amid a shift in its business model away from primary care and toward specialty products.

You may also be interested in...



Daiichi Closing Indian Site As Global Restructuring Continues

Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC088447

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel